Header Logo

Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer?

Di Nunno V, Santoni M, Massari F. Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer? Lancet Oncol. 2018 09; 19(9):e437.

View in: PubMed